Search Within

Shirley M Bartido

Formats
  1. Meeting Abstract (25)
  2. Journal Article (11)
Groups
  1. Sloan Kettering Institute Faculty (33)
  2. Department of Medicine (29)
  3. GSK Faculty (29)
  4. Hematologic Malignancies, Division of (29)
  5. Center for Hematologic Malignancies (27)
  6. Hematologic Malignancies Research (26)

More Groups

People
  1. Isabelle Riviere (28)
  2. Michel Sadelain (26)
  3. Xiuyan Wang (24)
  4. Renier Brentjens (17)
  5. Jolanta Stefanski (16)
  6. Clare Taylor (15)

More People

Years
  1. 2015 (1)
  2. 2014 (7)
  3. 2013 (9)
  4. 2012 (6)
  5. 2011 (2)
  6. 2010 (1)

More Years

Publications
  1. Blood (9)
  2. Journal of Clinical Oncology (6)
  3. Molecular Therapy (5)
  4. Journal of Immunotherapy (2)
  5. Pigment Cell Research (2)
  6. Science Translational Medicine (2)

More Publications

Publishers
  1. American Society of Hematology (9)
  2. American Society of Clinical Oncology (6)
  3. Nature Publishing Group (5)
  4. American Association for Cancer Research (3)
  5. Lippincott Williams & Wilkins (3)
  6. Wiley Blackwell (3)

More Publishers

Results (36)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor
    Journal Article

    Wang, X.; Olszewska, M.; Qu, J.; Wasielewska, T.; Bartido, S.; Hermetet, G.; Sadelain, M.; Rivière, I.
    Journal of Immunotherapy (2015)

    Fulltext@MSK | Save
  • Phase I trial of autologous CD19-targeted CAR-modified T cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bartido, S.; Sadelain, M.; Brentjens, R. J.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
    Meeting Abstract

    Sadelain, M.; Brentjens, R.; Davila, M.; Riviere, I.; Wang, X. Y.; Bartido, S.; Park, J.; Bouhassira, D.; Curran, K.; Chung, S.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Phase I trial of autologous Cd19-targeted car-modified T cells as consolidation after purine analog-based first-line therapy in patients with previously untreated cll
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X.; Bartido, S.; Sadelain, M.; Brentjens, R. J.
    Haematologica (2014)

    Fulltext@MSK | Save
  • Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
    Meeting Abstract

    Brentjens, R.; Davila, M.; Riviere, I.; Wang, X. Y.; Bartido, S.; Park, J.; Bouhassira, D.; Curran, K.; Chung, S.; Stefanski, J.; more...
    Molecular Therapy (2014)

    Fulltext@MSK | Save
  • Cell therapy products and bioreactors-developing a closed system
    Meeting Abstract

    Bartido, S.
    Human Gene Therapy (2014)

    Fulltext@MSK | Save
  • Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation
    Journal Article

    Boulad, F.; Wang, X.; Qu, J.; Taylor, C.; Ferro, L.; Karponi, G.; Bartido, S.; Giardina, P.; Heller, G.; Prockop, S. E.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
    Journal Article

    Davila, M. L.; Riviere, I.; Wang, X.; Bartido, S.; Park, J.; Curran, K.; Chung, S. S.; Stefanski, J.; Borquez-Ojeda, O.; Olszewska, M.; more...
    Science Translational Medicine (2014)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR(+)) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Hullings, M.; Arauz, G.; Bartido, S.; Lewis, J. S.; Schoder, H.; Zanzonico, P.; Scher, H. I.; Sadelain, M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR(+)) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Hullings, M.; Arauz, G.; Bartido, S.; Lewis, J. S.; Schoder, H.; Zanzonico, P.; Scher, H. I.; Riviere, I.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save